Cue Health Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Cue Health Inc (HLTH) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Cue Health Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 71M vs 1,057,685M combined for tracked competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+6.0% annualized vs trailing 12 months), vs decelerating (-6.8%) for its tracked peer group.
- Growth: Cue Health Inc generated -87.2% revenue growth year over year in Q4 2023, vs 1.2% for its tracked competitors combined.
- Profitability: Its -789.6% net margin compares with 4.7% for the peer group.
- Peer revenue share: Cue Health Inc accounted for 0.0% of combined revenue among its tracked peer group, down from 0.1% a year earlier.
- Peer differentiation: Revenue per employee of $0.89M compares with $0.35M for the peer group (2.5x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
HLTH Sales vs. its Competitors, Q4 2023
Cue Health Inc reported revenue contraction of 87.19 % year on year in Q4 2023, below its competitors' combined revenue growth of 1.23 %.
With a net margin of -789.62 %, Cue Health Inc reported lower profitability than its competitors (4.66 %).
Cue Health Inc generated 0.01 % of the combined sales of its peer group, down from 0.06 % a year earlier.
Cue Health Inc vs. its Competitors, Q4 2023
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Cue Health Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Cue Health Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (5) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (4) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Cue Health Inc's competitor groups requires a Commercial License.
For context: the Laboratory Analytical Instruments industry grew revenue 13.3% year over year, combined, vs -87.2% for Cue Health Inc. Cue Health Inc's share of combined industry revenue moved from 1.54% to 0.17%, a loss of 1.36 percentage points.
Cue Health Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Cue Health Inc | No | No | No | Yes |
| Competitors combined (18) | ||||
| High-Confidence Competitors (6) | ||||
| Similar Growth & Profitability (8) | 0.00 % (0 of 8) | 25.00 % (2 of 8) | 25.00 % (2 of 8) | 62.50 % (5 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
HLTH Stock Performance relative to its Competitors
HLTH Stock Performance relative to High-Confidence Competitors
HLTH Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | American Well Corporation | 282.9% | Outperformed |
| 2 | Thermo Fisher Scientific Inc | 282.9% | Outperformed |
| 3 | Becton Dickinson And Company | 282.9% | Outperformed |
| 4 | Quest Diagnostics Inc | 282.9% | Outperformed |
| 5 | Reflect Scientific Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Cue Health Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Cue Health Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Cue Health Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Cue Health Inc | 4,541.54 | 70.94 |
| Walmart Inc | 867,447.94 | 735,840.00 |
| Thermo Fisher Scientific Inc | 251,760.60 | 46,336.00 |
| Abbott Laboratories | 176,419.43 | 45,134.00 |
| Danaher Corporation | 160,858.71 | 25,107.00 |
| Becton Dickinson And Company | 50,582.30 | 20,840.00 |
| SUBTOTAL | 1,638,086.39 | 1,058,801.64 |
Sign in to see all competitors of Cue Health Inc .
Sources: Cue Health Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Cue Health Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Cue Health Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| American Well, Inc. | Named by the company | 85% |
| 1Life Healthcare, Inc. (d/b/a OneMedical) | Named by the company | 85% |
| Hims & Hers Health, Inc. | Named by the company | 85% |
| Co diagnostics Inc | Named by the company | 85% |
| Teladoc Health, Inc. | Named by the company | 85% |
| Amazon.com, Inc. | Named by the company | 85% |
| Kroger Co | Named by the company | 85% |
| Quest Diagnostics Inc | Named by the company | 85% |
| Genmark Diagnostics Inc | Named by the company | 85% |
| Walmart Inc | Named by the company | 85% |
| Thermo Fisher Scientific Inc | Named by the company | 85% |
| Abbott Laboratories | Named by the company | 85% |
| Danaher Corporation | Named by the company | 85% |
| Qiagen N v | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Cue Health Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Cue Health Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Walmart Inc | Walmart US 66.44 % |
| Thermo Fisher Scientific Inc | Clinical Research 19.98 % |
| Abbott Laboratories | Diabetes Care 17.78 % |
| Danaher Corporation | Diagnostics 39.36 % |
| Becton Dickinson And Company | Medical Essentials 34.94 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Cue Health Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Cue Health Inc | 4,542 | 886,700 | -4,668,300 |
| Walmart Inc | 867,448 | 350,400 | 10,714 |
| Thermo Fisher Scientific Inc | 251,761 | 370,688 | 55,912 |
| Abbott Laboratories | 176,419 | 392,470 | 54,574 |
| Danaher Corporation | 160,859 | 418,450 | 66,733 |
| Becton Dickinson And Company | 50,582 | 289,444 | 13,069 |
| PEERS TOTAL | 1,633,545 | 349,261 | 14,402 |
Cue Health Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Cue Health Inc | Non-US 0.85 % |
| Thermo Fisher Scientific Inc | North America 51.27 % |
| Abbott Laboratories | Non-US 61.62 % |
| Danaher Corporation | North America 39.49 % |
| Becton Dickinson And Company | United States 61.88 % |
| Hologic Inc | Non-US 30.23 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Cue Health Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 28 companies in Cue Health Inc's industry classification, broader than the peer set above. Market cap in millions of $.Cue Health Inc ranks #0 of 28 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 1,482, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Agilent Technologies inc | 49,584 | 21.65 % |
| 2 | Waters Corporation | 43,498 | 18.99 % |
| 3 | Illumina Inc | 41,601 | 18.16 % |
| 4 | Mettler toledo International Inc | 31,162 | 13.61 % |
| 5 | Revvity Inc | 1,234 | 5.2% |
| 6 | 10x Genomics Inc | 1,234 | 5.2% |
| 7 | Avantor Inc | 1,234 | 5.2% |
| 8 | Bio rad Laboratories Inc | 1,234 | 5.2% |
| 9 | Bruker Corporation | 1,234 | 5.2% |
| 10 | Alamar Biosciences Inc | 1,234 | 5.2% |
| 0 | Cue Health Inc | - | 0.00 % |
Market cap and industry share for the rest of Cue Health Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-09-28.
Cue Health Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Laboratory Analytical Instruments industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (45 companies).| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | -79.16 % | 40.40 % (avg) | -119.6 pp |
| Operating Margin | -556.63 % | industry median | -478.6 pp |
| EBITDA Margin | -444.32 % | -18.51 % (avg) | -425.8 pp |
| Capital Intensity (Capex / Revenue) | 27.91 % | 3.93 % (avg) | +24.0 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Cue Health Inc's Valuation vs Competitive Position
Valuation multiples vs the Laboratory Analytical Instruments industry average (45 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 34.1x | - |
| EV / EBITDA | - | 22.1x | - |
| P/B | 0.1x | 2.6x | -2.5x |
| Return on Equity | -95.88 % | industry aggregate | -96.02 % |
| Return on Invested Capital | -47.92 % | -11.56 % (avg) | -36.36 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Cue Health Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2021 | 2022 | 2023 |
|---|---|---|---|
| Revenue Growth | 117.95 % | -21.78 % | -85.33 % |
| Operating Margin | 30.77 % | -42.54 % | -556.63 % |
| Return on Invested Capital | 19.12 % | -15.52 % | -47.92 % |
| P/E | 6.3x | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Cue Health Inc's Strategic Group Map
Every company in Cue Health Inc's industry and named-competitor list, plotted by trailing 12-month revenue growth and operating margin. Cue Health Inc is shown in red; its closest peers by combined growth, margin and ROIC (the Similar Growth & Profitability group above) are labeled.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Cue Health Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 1,482 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | High (capital intensive) | Capital intensity (capex / revenue) of 27.91 % vs industry average 3.93 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Cue Health Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Cue Health Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Cue Health Inc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Cue Health Inc falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Cue Health Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+6.0% annualized vs trailing 12 months).
Weaknesses
- Operating margin 478.6 points below the industry median.
- Return on equity 96.0 points below the industry aggregate.
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
No rule matched.
Threats
- Losing revenue share to the broader industry (-1.4 points over the past year).
- Tracked peer group's revenue run-rate is broadly decelerating (-6.8% annualized).
- High capital intensity requires continuous reinvestment just to keep pace with the industry.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Cue Health Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Cue Health Inc | 2.20 | 3.54 | - |
| Walmart Inc | 0.10 | 0.78 | 0.38 |
| Thermo Fisher Scientific Inc | 0.32 | 1.62 | 0.78 |
| Abbott Laboratories | 0.47 | 1.60 | 0.35 |
| Danaher Corporation | - | 1.73 | 0.40 |
| Becton Dickinson And Company | 0.10 | 1.00 | 0.73 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Cue Health Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Cue Health Inc | Q4 2023 | -87.2 % | - |
| Walmart Inc | Q2 2026 | +5.9 % | -8.7 % |
| Thermo Fisher Scientific Inc | Q2 2026 | +10.5 % | +7.6 % |
| Abbott Laboratories | Q1 2026 | +7.8 % | -18.7 % |
| Danaher Corporation | Q2 2026 | +5.5 % | +56.8 % |
| Becton Dickinson And Company | Q2 2026 | +5.4 % | -34.3 % |
| PEERS TOTAL | +5.9 % | -3.4 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Cue Health Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Cue Health Inc | Q4 2023 | -60.6 % | -81.8 % |
| Walmart Inc | Q2 2026 | +4.5 % | +16.7 % |
| Thermo Fisher Scientific Inc | Q2 2026 | +142.5 % | +53.1 % |
| Abbott Laboratories | Q1 2026 | +9.4 % | -17.6 % |
| Danaher Corporation | Q2 2026 | +10.0 % | +8.5 % |
| Becton Dickinson And Company | Q2 2026 | +7.1 % | -12.8 % |
Cue Health Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Cue Health Inc | - | - | - |
| Walmart Inc | 7.78% | 13.37% | 21.78% |
| Thermo Fisher Scientific Inc | 6.36% | 7.71% | 13.37% |
| Abbott Laboratories | 6.87% | 8.15% | 12.09% |
| Danaher Corporation | 4.72% | 5.44% | 7.66% |
| Becton Dickinson And Company | 1.77% | 2.22% | 3.79% |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Cue Health Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Cue Health Inc | - | 64.02 |
| Walmart Inc | 39.25 | 1.18 |
| Thermo Fisher Scientific Inc | 36.52 | 5.43 |
| Abbott Laboratories | 28.13 | 3.91 |
| Danaher Corporation | 40.45 | 6.41 |
| Becton Dickinson And Company | 55.54 | 2.43 |
| PEERS AVERAGE | 37.85 | 1.55 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.